title: Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?
abstract: OBJECTIVE
  Calumenin, a molecular chaperone, exerts a regulatory effect on the vitamin K-dependent γ-carboxylation redox cycle that inhibits transfer of the reduced vitamin K from VKORC1, the pharmacological target of warfarin, to the γ-carboxylase. Because of its polymorphic structure and central role in the warfarin metabolic pathway, a contributory role for calumenin to warfarin dose variability has been posited. The current study sought to validate modulation of therapeutic dosing requirements by a single nucleotide polymorphisms (SNP) occurring in the calumenin gene (CALU) reported in previous studies. The CALU SNP was further modeled to detect interaction with SNPs occurring in VKORC1, CYP2C9, and CYP4F2 genes and characterize any additional contribution to variability in therapeutic warfarin dose requirement.
  
  
  METHODS
  The study was undertaken in an established, well-characterized cohort of subjects treated with warfarin in the Anticoagulation Clinic of Marshfield Clinic in Marshfield, Wisconsin.
  
  
  METHODS
  Subjects (N=491) previously genotyped for SNPS known to contribute variability to therapeutic warfarin dose requirement were genotyped for CALU SNP rs1043550, using TaqMan assays. Contribution of CALU SNP rs1043550 was modeled relative to other genotypic and phenotypic characteristics including gender, diagnosis, age, body surface area, underlying indication for warfarin, comorbidities, and pharmacological exposures. Interaction between SNPs impacting on warfarin dose requirements and calumenin SNPs was also modeled.
  
  
  RESULTS
  Small differences in warfarin dosing requirements detected among individuals encoding the mutant G allele in the calumenin SNP were not statistically or clinically significant relative to therapeutic warfarin dose requirement and did not independently contribute significantly to the warfarin dosing model. Interaction between calumenin and VKORC1 SNPs contributed only minor additional variability to that ascribed to the wild type VKORC1 genotype.
  
  
  CONCLUSIONS
  The impact of the CALU SNP on warfarin dose variability was minor and did not contribute significantly to therapeutic warfarin dose requirement in our study cohort. While no contribution was noted for the SNP examined in the present study, further examination of interaction between genetic elements contributing major impact on therapeutic warfarin dose requirements and genes exhibiting a lesser contribution is warranted.
authors: Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449, USA. glurichi@mcrf.mfldclin.edu
authors: Ingrid
authors: I
authors: Glurich
authors: Richard L
authors: RL
authors: Berg
authors: James K
authors: JK
authors: Burmester
mesh_terms: D000483:Alleles; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002135:Calcium-Binding Proteins / Q000235:genetics*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006349:Heart Valve Diseases / Q000188:drug therapy; D006801:Humans; D008297:Male; D008957:Models, Genetic; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D013923:Thromboembolism / Q000188:drug therapy; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; C510527:CALU protein, human; D002135:Calcium-Binding Proteins; D014859:Warfarin
keywords: Anticoagulation; Calumenin; VKORC1; Vitamin K; Warfarin
references: Thromb Res. 2007;120(2):181-6
references: 17049586
references: J Biol Chem. 2004 Jun 11;279(24):25276-83
references: 15075329
references: Hum Genet. 2007 Mar;121(1):23-34
references: 17048007
references: Genomics. 1998 Apr 15;49(2):331-3
references: 9598325
references: Blood. 2006 Dec 1;108(12):3757-60
references: 16902154
references: Clin Med Res. 2007 Mar;5(1):8-16
references: 17456829
references: Genet Med. 2011 Jun;13(6):509-18
references: 21423021
references: Pharmacogenetics. 2004 Aug;14(8):539-47
references: 15284536
references: Pharmacogenomics. 2012 Mar;13(4):407-18
references: 22329724
references: Clin Pharmacol Ther. 2010 Apr;87(4):445-51
references: 20200517
references: Eur J Clin Pharmacol. 2010 Mar;66(3):253-60
references: 20020283
references: Blood. 2008 Apr 15;111(8):4106-12
references: 18250228
references: Annu Rev Biochem. 1985;54:459-77
references: 3896125
references: Heart Fail Rev. 2010 May;15(3):239-48
references: 18998206
references: Circulation. 2006 Mar 28;113(12):1615-21
references: 16549638
references: Blood. 2008 Aug 15;112(4):1022-7
references: 18535201
references: Annu Rev Nutr. 2005;25:127-49
references: 16011462
references: J Biol Chem. 1997 Jul 18;272(29):18232-9
references: 9218460
references: J Thromb Haemost. 2007 Aug;5(8):1701-6
references: 17596133
references: FASEB J. 2001 Nov;15(13):2542-4
references: 11641264
references: Thromb Haemost. 2006 Feb;95(2):205-11
references: 16493479
references: PLoS Genet. 2009 Mar;5(3):e1000433
references: 19300499